Should brachytherapy be considered a therapeutic option in localized prostate cancer? (Q41249068)

28 September 2017

1 reference

title

Should brachytherapy be considered a therapeutic option in localized prostate cancer? (English)

1 reference

28 September 2017

1 reference

Blasko JC

1

1 reference

28 September 2017

Ragde H

2

1 reference

28 September 2017

Luse RW

3

1 reference

28 September 2017

Sylvester JE

4

1 reference

28 September 2017

Cavanagh W

5

1 reference

28 September 2017

Grimm PD

6

1 reference

28 September 2017

publication date

1 November 1996

1 reference

Urologic Clinics of North America

28 September 2017

published in

1 reference

28 September 2017

volume

23

1 reference

28 September 2017

issue

4

1 reference

28 September 2017

page(s)

633-650

1 reference

Deferred treatment in clinically localised prostatic carcinoma.

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Short-term morbidity from CT-planned transperineal I-125 prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Comments on the treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome--regarding Zietman et al., IJROBP 32:287-292; 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

5-Year Tumor Recurrence Rates After Anatomical Radical Retropubic Prostatectomy For Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Proliferative cell nuclear antigen in postradiotherapy prostate biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Preoperative irradiation, lymphadenectomy, and 125iodine implantation for patients with localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Preliminary results of a hyperfractionated dose escalation study for locally advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

125Iodine implantation after lymphadenectomy in early carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Value of computed tomography in interstitial 125I brachytherapy of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

The effect of dose on local control of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Ultrasonically guided 125iodine seed implantation with external radiation in management of localized prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

High 10-year survival rate in patients with early, untreated prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Combination of external beam irradiation and multiple-site perineal applicator (MUPIT) for treatment of locally advanced or recurrent prostatic, anorectal, and gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Dose-rate effects in synchronous mammalian cells in culture. II. A comparison of the life cycle of HeLa cells during continuous irradiation or multiple-dose fractionation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Prostatic cancer therapy: comparison of external-beam radiation and I-125 seed implantation treatment of stages B and C neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Pathology of carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

A pathologist's view of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Permanent interstitial implantation using palladium-103: the New York Medical College preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Predictors of survival after a positive post-irradiation prostate biopsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

A CT-based evaluation method for permanent implants: application to prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Localization of the prostatic apex for radiation therapy using implanted markers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Temporary iridium-192 implant in the management of carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

An improved method for computerized tomography-planned transperineal 125iodine prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Short-term freedom from disease progression after I-125 prostate implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Retropubic Implantation of Iodine 125 in the Treatment of Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Prostate Specific Antigen as an Outcome Variable for T1 and T2 Prostate Cancer Treated by Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

Radical Prostatectomy and Radical Radiation Therapy for Clinical Stages T1 to 2 Adenocarcinoma of the Prostate: New Insights into Outcome from Repeat Biopsy and Prostate Specific Antigen Followup

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970342-6

7 January 2021

10.1016/S0094-0143(05)70342-6

Identifiers

DOI

1 reference

28 September 2017

1 reference